Solid dose formulations remain the preferred format for dosages and, as a result, the corresponding market looks healthy with strong prospects for continued growth. Nevertheless, the market faces multiple challenges – but it also offers opportunities for contract development and manufacturing organisations (CDMOs) that possess the advanced scientific and technological skills to provide customers with solutions that combine an extensive range of resources, facilities and service capabilities.
One of these challenges is the increasing demand for capabilities that support the formulation and development of fixed dose combination drugs. This need addresses increased patient adherence to the prescribed treatment and, in some cases, improved clinical benefits. Additionally, it extends differentiation of branded products in the marketplace.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.